Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
The impact of respiratory infections on public health is increasing and lower respiratory tract infections are a major cause of morbidity and mortality. We are also facing a worldwide burst of antibiotic bacterial resistance. The new fluoroquinolones have an excellent spectrum covering the most important respiratory pathogens, including atypical and 'typical' pathogens. Pharmacokinetic and dynamic properties of the new fluoroquinolones have a significant impact on their clinical and bacteriological efficacy. They cause a concentration-dependent killing with a sustained postantibiotic effect. Fluoroquinolones combine exceptional efficacy with cost-effectiveness. Not surprisingly, different guidelines have inserted these agents among the drugs of choice in the empirical therapy of community-acquired pneumonia. This review discusses the more recent data on bacteriological and clinical activity and critically analyses the risks of a potential overuse of this valuable new class of drugs.
Blasi
Francesco
F
Institute of Respiratory, University of Milan, IRCCS Ospedale Maggiore Milan, Italy. francesco.blasi@unimi.it
Tarsia
Paolo
P
Cosentini
Roberto
R
Cazzola
Mario
M
Allegra
Luigi
L
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001991:Bronchitis / Q000150:complications; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones